Tags

Type your tag names separated by a space and hit enter

[New pneumococcal vaccine].
Bull Acad Natl Med. 2003; 187(8):1477-86; discussion 1486-8.BA

Abstract

Streptococcus Pneumoniae is the main pathogen bacteria responsible for invasive diseases (bacteremia, meningitis) in children less than 2 years of age. The new conjugate heptavalent pneumococcal vaccine (7 polysaccharide serotypes 4, 6B, 9V, 14, 18C, 19F, 23F conjugated with the CRP 197 protein derived from diphteria anatoxin) is a great advance. This vaccine is well tolerated, immunogenic and efficient in infant. His efficacy in invasive pneumococcal diseases is more than 95%. The reduction of pneumonia (with 2.5 cm X-Ray opacity) was 32.2% in the first year of age and 23.4% in the two first years in the vaccinated group. The efficacy in acute otitis media is poor French indications of this vaccine, limited to infants under 2 years of age with further risk factor, might be extended to all the infants under 2 years of age.

Authors+Show Affiliations

Service de Pédiatrie-CHU Jean Verdier-93140 Bondy.

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

15146579

Citation

Gaudelus, Joël. "[New Pneumococcal Vaccine]." Bulletin De l'Academie Nationale De Medecine, vol. 187, no. 8, 2003, pp. 1477-86; discussion 1486-8.
Gaudelus J. [New pneumococcal vaccine]. Bull Acad Natl Med. 2003;187(8):1477-86; discussion 1486-8.
Gaudelus, J. (2003). [New pneumococcal vaccine]. Bulletin De l'Academie Nationale De Medecine, 187(8), 1477-86; discussion 1486-8.
Gaudelus J. [New Pneumococcal Vaccine]. Bull Acad Natl Med. 2003;187(8):1477-86; discussion 1486-8. PubMed PMID: 15146579.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [New pneumococcal vaccine]. A1 - Gaudelus,Joël, PY - 2004/5/19/pubmed PY - 2004/7/24/medline PY - 2004/5/19/entrez SP - 1477-86; discussion 1486-8 JF - Bulletin de l'Academie nationale de medecine JO - Bull Acad Natl Med VL - 187 IS - 8 N2 - Streptococcus Pneumoniae is the main pathogen bacteria responsible for invasive diseases (bacteremia, meningitis) in children less than 2 years of age. The new conjugate heptavalent pneumococcal vaccine (7 polysaccharide serotypes 4, 6B, 9V, 14, 18C, 19F, 23F conjugated with the CRP 197 protein derived from diphteria anatoxin) is a great advance. This vaccine is well tolerated, immunogenic and efficient in infant. His efficacy in invasive pneumococcal diseases is more than 95%. The reduction of pneumonia (with 2.5 cm X-Ray opacity) was 32.2% in the first year of age and 23.4% in the two first years in the vaccinated group. The efficacy in acute otitis media is poor French indications of this vaccine, limited to infants under 2 years of age with further risk factor, might be extended to all the infants under 2 years of age. SN - 0001-4079 UR - https://www.unboundmedicine.com/medline/citation/15146579/[New_pneumococcal_vaccine]_ L2 - https://medlineplus.gov/pneumococcalinfections.html DB - PRIME DP - Unbound Medicine ER -